-+ 0.00%
-+ 0.00%
-+ 0.00%
FDA Approves Expansion of Alpha Tau’s Glioblastoma Trial to 20 Patients
Share
Listen to the news
FDA Approves Expansion of Alpha Tau’s Glioblastoma Trial to 20 Patients
  • FDA cleared Alpha Tau Medical to expand its Alpha DaRT REGAIN trial in recurrent glioblastoma to 20 patients from 10.
  • The expanded protocol adds progression-free survival and quality-of-life assessments, with an additional interim analysis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190830PRIMZONEFULLFEED9848283) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending